Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27046916 | 0.88 | LMNA (0.69) | LMNAMAPTCYP19A1CYP3A4 | |
| SCHEMBL17775774 | 0.88 | LMNA (0.69) | LMNAMAPTCYP19A1CYP3A4 | |
| SCHEMBL27046918 | 0.87 | LMNA (0.67) | LMNAMAPTCYP19A1CYP3A4 | |
| SCHEMBL8939666 | 0.86 | LMNA (0.73) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL17775770 | 0.84 | LMNA (0.77) | LMNAMAPTCYP19A1CYP3A4 | |
| SCHEMBL27046922 | 0.83 | LMNA (0.75) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| Methandrostenolone SCHEMBL4435272 | 0.81 | LMNA (1.00) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| Methandrostenolone SCHEMBL8408550 | 0.81 | LMNA (1.00) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| SCHEMBL5270893 | 0.81 | LMNA (0.81) | LMNAMAPTCYP19A1CYP3A4HSD17B10 | |
| Methandrostenolone SCHEMBL21177905 | 0.81 | LMNA (1.00) | LMNAMAPTCYP19A1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | LMNA 3030/4885MAPT 4345/4885CYP19A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.